New combo vaccine targets flu, RSV, and more in early trial

NCT ID NCT06850051

First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 24 times

Summary

This early-stage study tested the safety and immune response of new vaccines that combine protection against flu, RSV, human metapneumovirus, and parainfluenza virus type 3. 270 healthy adults aged 18 to 49 received a single shot of one of the vaccine formulas. Researchers monitored side effects and measured antibody levels to see how well the vaccines worked.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emeritus Research

    Camberwell, Victoria, 3124, Australia

  • Griffith University

    Southport, Queensland, 4215, Australia

  • Paratus Clinical

    Blacktown, New South Wales, 2148, Australia

  • Paratus Clinical

    Herston, Queensland, 4006, Australia

  • University of Sunshine Coast Clinical Trials

    Morayfield, Queensland, 4506, Australia

  • University of Sunshine Coast Clinical Trials

    South Brisbane, Queensland, 4101, Australia

Conditions

Explore the condition pages connected to this study.